About Owkin
Owkin is an AI precision medicine company with a vision to find the right drug for every patient.
Headquarters
Owkin, New York
Founded
2016-01-01
Industry
Artificial Intelligence (AI), Biotechnology, Clinical Trials, Machine Learning, Pharmaceutical, Precision Medicine
Last Funding Type
Series B
Valuation
3
Total Funding
$304.10 million dollars
IPO Status
Private
Financial
Owkin may be growing as indicated by the launch of a new startup by its top executives, which aims to build a large language model for biotech, suggesting innovation and expansion within its niche in AI and biotechnology. Additionally, the hiring of a former BioMarin CEO at Owkin signals strategic leadership growth, potentially enhancing the company's expertise and industry connections. Furthermore, the inclusion of Owkin in a list of nineteen biotech companies in France that are making a difference highlights its recognition in the biotech community, which may contribute to its positive reputation and business opportunities.
Owkin is advancing AI precision medicine through various research areas. They are developing systems for image classification and preprocessing, which involve segmenting images into regions of interest using convolutional neural networks. Their work includes detecting tertiary lymphoid structures in histology images and predicting breast cancer prognosis by analyzing whole slide images. Additionally, Owkin is focused on identifying features of pancreatic ductal adenocarcinoma from histopathology slides. These efforts highlight their commitment to enhancing diagnostic and prognostic capabilities in medicine.
Owkin is advancing AI precision medicine through various research areas. They are developing systems for image classification and preprocessing, which involve segmenting images into regions of interest using convolutional neural networks. Their work includes detecting tertiary lymphoid structures in histology images and predicting breast cancer prognosis by analyzing whole slide images. Additionally, Owkin is focused on identifying features of pancreatic ductal adenocarcinoma from histopathology slides. These efforts highlight their commitment to enhancing diagnostic and prognostic capabilities in medicine.
Funding Rounds
8
Number of Lead Investors
8
Total Funding Amount
$304.10 million dollars
Number of Investors
16